nerve cells News
-
Link between pesticides and Parkinson`s disease
A study conducted in the United States, published this week, adds to the body of research linking pesticides and Parkinson's. Researchers compared people with Parkinson's to family members and found that those with Parkinson's had had greater exposure to pesticides. Kieran Breen, Director of Research at the Parkinson’s Disease Society (PDS) said: 'The association between pesticides and ...
-
Kadimastem Expands R&D Program to Include Multiple Sclerosis
Ness Ziona, Science Park, May 18, 2022 - Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, is expanding its R&D activity with the exploration of developing a treatment for Multiple Sclerosis (MS). As part of this initiative, the company has signed a service agreement with Hadasit Medical Research Services ...
-
Woolsey Pharmaceuticals Begins ALS Study
NEW YORK, December 13, 2021 — Woolsey Pharmaceuticals, a clinical-stage company developing treatments for neurodegenerative diseases, today announced it commenced a study of BRAVYL in Amyoptrophic Lateral Sclerosis (ALS) patients. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. ALS is part of a wider group of disorders known as ...
-
TIKOMED secures 5 M € funding for the clinical development of ILB™ and IBSOLVMIR®
TIKOMED, a Swedish privately-held biopharmaceutical company today announced that it has successfully completed a €5 million round of financing from current investors. The capital will primarily be used to support the ongoing clinical development program for ILB™ and IBSOLVMIR®, advancing the company’s position within the treatment of acute and degenerative neurological ...
By TIKOMED AB
-
Woolsey Pharmaceuticals Receives Positive Opinion on Orphan Drug Application from the European Medicines Agency for the Treatment of ALS with BRAVYL
NEW YORK, NY – January 3, 2021 – Woolsey Pharmaceuticals, a repurposed therapeutics development company announced that the European Medicines Agency’s Committee for Orphan Medicinal Product has issued a positive opinion on the orphan drug application for the Company’s investigational drug, BRAVYL® (oral fasudil), for the treatment of Amyotrophic Lateral Sclerosis ...
-
Kadimastem Receives Grant for a Total Budget of $3.1 million from the Israeli Innovation Authority
NESS ZIONA, ISRAEL, March 3, 2022 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, has received a grant from the Israel Innovation Authority (IIA) for a total budget of NIS 10 million ($3.1 million) and a net grant of NIS 4 million ($1.25 million). The funds will be used to advance the filing of an IND ...
-
Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society
Data from IND-enabling studies show accurate delivery, targeted biodistribution, favorable safety profile, durable suppression of seizures and reduction in disease pathology A first-in-human Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy has been initiated and will begin recruiting soon Neurona Therapeutics, a clinical-stage biotherapeutics ...
-
CD Bioparticles Expands Lipid System Portfolio by the Launch of Sphingolipids
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, has now expanded lipid system portfolio and launched a series of Sphingolipids products to support customers' scientific research. CD Bioparticles now offers more choices for researchers to choose from and use in lipid system applications, such as Ceramides, Sphingosines, Sphingomyelin, ...
-
NIH investigators discover new mechanism that may be important for learning and memory
New findings in mice suggest that the timing when the neurotransmitter acetylcholine is released in the brain's hippocampus may play a key role in regulating the strength of nerve cell connections, called synapses. Understanding the complex nature of neuronal signaling at synapses could lead to better understanding of learning and memory, and novel treatments for relevant disorders, such as ...
-
Creative Proteomics Upgraded Exosome Proteomics Service to Accelerate Biomarker Discovery Research
Creative Proteomics, an integrated CRO company committed to providing a full range of services to support various proteome-related research projects from identification of single proteins to large-scale proteomic studies, has recently upgraded its fully-developed Exosome Proteomics Service to identify and quantify the proteins in exosomes. The company can also help discover biomarkers after ...
-
NIH investigators discover new mechanism that may be important for learning and memory
New findings in mice suggest that the timing when the neurotransmitter acetylcholine is released in the brain's hippocampus may play a key role in regulating the strength of nerve cell connections, called synapses. Understanding the complex nature of neuronal signaling at synapses could lead to better understanding of learning and memory, and novel treatments for relevant disorders, such as ...
-
TIKOMED’S ILB® resolves inflammatory scarring and promotes functional tissue repair in data published in npj Regenerative Medicine
A new study on TIKOMED’s lead drug candidate, ILB®, was published in npj Regenerative Medicine today. The peer-reviewed data from rodent and human disease models showed that ILB® leads to tissue remodelling, reduced fibrosis and functional tissue regeneration – observations indicating the potential of ILB® to alleviate fibrotic diseases. Professor Ann Logan, from the ...
By TIKOMED AB
-
Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate
TEL AVIV & WENDELSHEIM, Germany--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG's lead compound anle138b and a related compound, sery433. Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with ...
By MODAG GmbH
-
BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson`s Disease
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson’s disease (PD). DA01, BlueRock’s pluripotent stem cell-derived dopaminergic neuron therapy, is under evaluation in a Phase 1 study. The FDA’s ...
-
An Overview of Glioblastoma
It is estimated that more than 240,000 cases of brain and nervous system tumors are diagnosed each year around the world. The most common and most lethal of these cancerous tumors are glioblastoma (GBM). What is Glioblastoma? Glioblastoma is a type of glioma, which is a brain tumor that begins in the star-shaped glial cells that surround and support nerve cells in the brain. GBM is a Grade IV ...
-
BlueRock Therapeutics Announces Closeout of First Cohort in Phase 1 Trial in Patients with Advanced Parkinson’s Disease
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the closeout of the first of two cohorts in its ongoing Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease. The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability and ...
-
BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson`s Disease
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in a Phase 1 (Ph1), open-label study of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease (PD). The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability, ...
-
BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson’s Disease
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced that Health Canada has given permission to initiate “Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson’s Disease (PD).” This is the first trial in Canada to study pluripotent stem cell-derived dopaminergic neurons in patients ...
-
BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson`s Disease
BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), announced today that the U.S. Food and Drug Administration (FDA) has cleared their Investigational New Drug (IND) application to proceed with a Phase 1 (Ph1) study in patients with advanced Parkinson’s disease (PD). ...
-
Lauren Sciences LLC awarded second grant for LAUR-301 from The ALS Association
New York, N.Y., April 19, 2016 -- Lauren Sciences LLC, private New York biotechnology company developing breakthrough V-SmartTM Nanomedicines for brain diseases, announced today award of second grant from The ALS Association. The ALS Association grant will support Lauren Sciences continued development of LAUR-301, its V-SmartTM Nanomedicine designed for ALS (amyotrophic lateral sclerosis), also ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you